文献速递胸部肿瘤放疗姑息放疗与转移瘤

非小细胞肺癌大分割姑息放化疗后食管炎的危险因素

Risk factors for esophagitis after hypofractionated palliative (chemo) radiotherapy for non-small cell lung cancer.
PubMed 文献 · Radiat Oncol · 2020-05-01

该回顾性研究分析了106例接受大分割姑息性放疗或放化疗的非小细胞肺癌患者,其中97例纳入分析,31%发生食管炎(26%为2-3级,无4-5级)。多因素分析显示食管Dmax是最强剂量学预测因子,同步化疗增加风险,口服类固醇降低风险;Dmax≥40 Gy时降低Dmean(≤20 Gy)有益。

要点

  • 大分割姑息治疗中31%发生食管炎,多为2-3级,无4-5级。
  • 食管Dmax是多因素分析中最强的剂量学预测因子。
  • 同步化疗增加食管炎风险,口服类固醇可能降低风险。

核心结论

  • 为减少大分割姑息治疗后食管炎,宜采用低于根治性NSCLC推荐值的食管剂量。
  • 除食管剂量外,同步放化疗是食管炎的主要危险因素。
  • 类固醇能否改变风险尚需进一步研究确认,或需排除未纳入数据库的基线变量混杂效应。

研究设计与样本

  • 回顾性分析2009至2017年接受姑息性放疗或放化疗的106例患者,97例符合条件纳入单因素和多因素分析。
  • 纳入标准:处方总剂量30-54 Gy,分次剂量2.5-4 Gy,食管剂量>1 Gy。
  • 食管炎按CTCAE 5.0标准评估急性食管炎≥1级。

主要发现

  • 40%患者接受15次2.8 Gy(42 Gy)治疗,28%同时接受CONRAD方案化疗(诱导及同步卡铂/长春瑞滨)。
  • 食管Dmax人群中位数为39 Gy,Dmean为15 Gy。
  • 31%患者发生食管炎(26%为2-3级,无4-5级)。
  • 多个剂量学参数(Dmax、Dmean、D5cc、V20、V30、V35、V40)与食管炎风险相关,多因素分析中Dmax优于其他剂量学变量。

关键数值与推荐

  • 食管Dmax≥40 Gy的患者中,降低Dmean(≤20 Gy)有益。
  • 同步化疗显著增加食管炎风险,口服类固醇药物降低风险。

临床怎么用

  • 大分割姑息性放化疗时应采用低于根治性NSCLC推荐的食管剂量约束。
  • 关注食管Dmax,并考虑同步化疗的风险,Dmax≥40 Gy时尽量将Dmean控制在≤20 Gy。

局限性

  • 回顾性研究设计。
  • 类固醇降低风险的作用可能受未纳入数据库的基线变量混杂影响,需进一步研究确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Esophagitis influences quality of life and might cause treatment interruption and hospitalization. Previous studies of risk factors focused on curative treatment for non-small cell lung cancer (NSCLC), which often involves concomitant chemoradiation (CRT). Given the uncertainty around extrapolation of dose constraints, we analyzed risk factors in patients treated with hypofractionated palliative regimens. PATIENTS AND METHODS: A retrospective review of 106 patients treated with palliative radiotherapy or CRT between 2009 and 2017 was performed. INCLUSION CRITERIA: prescribed total dose 30-54 Gy, dose per fraction 2.5-4 Gy, esophageal dose > 1 Gy. Uni- and multivariate analyses were performed in 97 eligible patients to identify predictive factors for acute esophagitis grade ≥ 1 (CTCAE 5.0). RESULTS: Forty percent of patients were treated with 15 fractions of 2.8 Gy (42 Gy) and 28% also received chemotherapy according to the CONRAD study regimen (induction and concomitant Carboplatin/Vinorelbine) published by the Norwegian Lung Cancer Group. Thirty-four percent were treated with 10 fractions of 3 Gy. Stage IV NSCLC was present in 47%. Esophagus Dmax was 39 Gy (population median) and Dmean 15 Gy. Overall 31% of patients developed esophagitis (26% grade 2-3, no grade 4-5). Several dosimetric parameters correlated with the risk of esophagitis (Dmax, Dmean, D5cc, V20, V30, V35, V40). Dmax outperformed other dosimetric variables in multivariate analysis. Furthermore, concomitant chemotherapy significantly increased the risk of esophagitis, while oral steroid medication reduced it. In patients with Dmax ≥40 Gy a reduced Dmean (≤20 Gy) was beneficial. CONCLUSION: In order to reduce esophagitis after hypofractionated palliative treatment lower doses than those recommended in curative NSCLC settings are preferable. Besides esophageal dose, CRT is the main risk factor for esophagitis. Additional work is needed to confirm that steroids are able to modify the risk (or to rule out confounding effects of baseline variables not included in our database).

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Nieder C, Imingen KS, Mannsåker B, et al. Risk factors for esophagitis after hypofractionated palliative (chemo) radiotherapy for non-small cell lung cancer. Radiat Oncol. 2020. PMID: 32357936. doi:10.1186/s13014-020-01550-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。